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Abstract
Background: The structural integrity of recombinant proteins is of critical importance to their
application as clinical treatments. Recombinant growth hormone preparations have been examined
by several methodologies. In this study recombinant human growth hormone (rhGH;
Genotropin®), expressed in E. coli K12, was structurally analyzed by two-dimensional gel
electrophoresis and MALDI-TOF-TOF, LC-MS and LC-MS/ MS sequencing of the resolved
peptides.
Results: Electrospray LC-MS analysis revealed one major protein with an average molecular mass
of 22126.8 Da and some additional minor components. Electrospray LC-MS/MS evaluation of the
enzymatically digested Genotropin® sample resulted in the identification of amino acid substitutions
at the residues M14, M125, and M170; di-methylation of K70 (or exchange to arginine); deamidation of
N149, and N152, and oxidation of M140, M125 and M170. Peak area comparison of the modified and
parental peptides indicates that these changes were present in ~2% of the recombinant
preparation.
Conclusion: Modifications of the recombinant human growth hormone may lead to structural or
conformational changes, modification of antigenicity and development of antibody formation in
treated subjects. Amino acid exchanges may be caused by differences between human and E. coli
codon usage and/or unknown copy editing mechanisms. While deamidation and oxidation can be
assigned to processing events, the mechanism for possible di-methylation of K70 remains unclear.
Background
The structural integrity of recombinant products gener-
ated by prokaryotic and eukaryotic organisms is a major
concern. Modifications such as amino acid sequence sub-
stitution/mutations of recombinant proteins may lead to
pharmacological inactivation, autoimmune phenomena
[1-3] and adverse effects [4,5]. Human growth hormone
(hGH) replacement is a frequent therapeutic intervention
[6,7]. Genetic changes in human growth hormone have
been linked to biological inactivity and disease: Lewis et al
(2004) reported that a growth hormone variant I179_M179
showed decreased ability to activate the extracellular sig-
nal-regulated kinase pathway and Binder et al. (2002)
described hGH deficiency due to mutations of the coding
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regions of the growth hormone-1 gene [8,9]. Zhu et al.
(2002) reported a case of hGH R183_H183. This single
mutation causes autosomal dominant growth hormone
deficiency type II by prolonged retention time of
R183_H183 aggregates into secretory granules [10].
However, although such changes can be detrimental, non
functional sequence alteration induced by poor editing of
recombinant proteins may act as a marker of growth hor-
mone abuse in situations such as athlete doping. We
therefore were highly interested in the homogeneity and
structure of rhGH preparations.
Genotropin® is expressed by E. coli, strain K12. It consists
of a single polypeptide chain containing 191 amino acids
and two disulfide bonds (C53-C165; C182-C189) [11] with a
molecular mass of 22 124 Da – representing the most
abundant growth hormone form in humans [12].
In humans two major hGH splicing variants have been
described, a 22 kDa protein and a 20 kDa protein, that
bind different sites at the growth hormone receptor and
serve different biological activities [13,14].
The genetic origin of hGH is the hGH-N gene, located on
the long arm of chromosome 17, in a 66-kbp cluster
region closely related to four other genes: hGH-V, hCS-A,
hCS-B and hCS-L. The hGH-N gene is expressed in both,
pituitary and several nonpituitary sites [12], all other gene
products are produced by placental syncytio-trophoblasts.
A series of posttranslational modifications of hGH have
been described and range from N-glycosylation, acetyla-
tion, deamidation, oxidation at M14 and M125 to polymer-
isation [12,15-18].
As mentioned above, Genotropin® is expressed by E. coli.
Since the fidelity of hGH translation in E. coli cannot rely
on copy editing [19,20], nor on correct codon usage [21-
23], there is a large potential for sequence errors. That's
why investigations of structural/sequential integrity,
including amino acid exchanges/mutations, and post
translational modifications of rhGH Genotropin® is of
particular interest to for modern medicine and
pharmacotherapy.
The aim of the present study was to investigate the homo-
geneity of a commercial available rhGH, Genotropin®.
This was achieved using two dimensional gel electro-
phoresis (2-DE), matrix-assisted laser desorption/ionisa-
tion mass spectrometry (MALDI-MS) followed by tandem
mass spectrometry (MALDI-MS/MS) and liquid chroma-
tography mass spectrometry (LC-MS) followed by tandem
mass spectrometry (LC-MS/MS). These modern analytical
tools provide definitive structural analysis independent of
antibody availability and specificity.
Results
Two dimensional gel electrophoresis
Two dimensional gel electrophoresis (2-DE) of 1 mg Gen-
otropin®  showed a multiple spot pattern with masses
between 20 000 and 35 000 Da and pIs from 4.5 to 7.0.
Several two dimensional (2D) gels with sample amounts
of 0.5, 1, 2, 5, 10, 20, 50, 100, 200 and 500 g of Genotro-
pin® were performed. Decreasing protein load showed
reduction of spot size and number and finally, limitation
to two spots of 22000 Da with pI of 5.3 and 5.4.
Neither MALDI-TOF-TOF nor LC-MS analysis of picked
gel spots indicated any modifications or isoforms in an
amount, that would explain differences between the two
spots.
Electrospray LC-MS measurements of the Genotropin® 
sample
Electrospray liquid chromatography – mass spectrometry
(LC-MS) measurements of the intact Genotropin® have
shown that the main product was a molecule with an aver-
age molecular weight (MW) of 22126.8 Da. The manufac-
turers had determined the average MW of Genotropin® to
be 22124 Da.
The mass difference of approximately 3 Da may originate
from the deconvulation of some broader, lower intensity
peaks. Several minor components could be also detected.
(Figure 1) The mass differences between the main product
(Nr. 1) and components Nr. 2–5 respectively indicate the
oxidation of several amino acid residues. Components
Nr.6 and Nr.7 show a mass discrepancy of approximately
+268 Da and -19 Da respectively. According to the ratios
of peak areas (Table 1), the sample consists to 84.4% of
the unmodified main component; the oxidation products
are present to 13.7% of the whole sample and the ratio of
other minor components, which may represent addi-
tional modifications or amino acid substitutions, is
approximately 2%.
Electrospray LC-MS/MS measurements following the 
tryptic digestion of the Genotropin® sample
Electrospray tandem liquid chromatography – mass spec-
trometry (LC-MS/MS) measurements of the samples pre-
pared from one dimensional SDS-PAGE indicated mass
differences at several peptides. Doubly or triply charged
ions were chosen for all MS/MS experiments due to their
better fragmentation pattern. Table 2 shows the sequences
of the modified peptides and possible explanations for
the mass discrepancies.Proteome Science 2005, 3:1 http://www.proteomesci.com/content/3/1/1
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A mass difference of +28 Da was detected at the position
K70 (Figure 2), could be explained by the di-methylation
of this residue, or by the exchange of this lysine to an
arginine. These modifications result in a mass difference
of 28.03 Da and 28.01 Da respectively. The accuracy of the
mass spectrometric detection was not high enough to dif-
ferentiate between these possibilities. Figure 2 shows the
fragment spectrum of the peptide EETQQKSNLELLR.
Intensive y ions verify that all residues have unchanged
masses except of K70, which makes the localization of the
mass discrepancy on that lysine residue unambiguous.
Reconstructed electrospray LC/MS spectrum of the Genotropin® sample Figure 1
Reconstructed electrospray LC/MS spectrum of the Genotropin® sample. The spectrum was recorded in positive 
ionization modus; 1 pM of the protein was injected. Detected average molecular masses: Nr.1.:22126.8 Da; Nr.2: 22143.5 Da; 
Nr.3: 22158.7 Da; Nr.4: 22174.4 Da; Nr.5: 22240.7 Da; Nr.6: 22395.9 Da; Nr7.: 22107.6 Da
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Table 1: Relative peak areas of the components detected by 
electrospray LC/MS measurement
Molecular mass (Da) Area (cps) Area (%)
22126.9 4909.8 84.4
22143.5 479.7 8.2
22158.7 121.5 2.1
22174.4 120.8 2.1
22107.6 76.9 1.3
22240.7 69.9 1.2
22395.9 40.4 0.7
Average molecular masses of the components detected in the LC/MS 
spectrum of 1 pM Genotropin® sample. The peak areas were 
calculated from the reconstructed spectrum (Figure 1) recorded in 
positive ionization.Proteome Science 2005, 3:1 http://www.proteomesci.com/content/3/1/1
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Deamidation of the amino acids N149 and N152 was also
detected. The molecular mass of the peptide RLEDGSPR
was decreased with 28 Da. The mass difference could be
localized to the N terminus of the peptide and might indi-
cate the substitution of R127 with a lysine or glutamine.
The mass difference of these residues is only 0.04 Da and
the accuracy of the mass spectrometric detection was not
high enough to differentiate between these amino acids.
Residues M14, M125 and M170 were observed partly oxi-
dized and in some cases the non oxidized residue showed
a mass discrepancy of -18 Da (Table 2). This phenomenon
is illustrated by Figure 3, which shows a product ion spec-
trum of the modified peptide LFDNAMLR. Fragment ions
from the y series verify the mass reduction at the M14 resi-
due. This mass difference can be explained by the replace-
ment of these methionines with isoleucines, which can be
originate from the substitution of the last base in the
genetic codon of methionine (M:ATG; I:ATT/C/A).
According to the ratios of the peak areas of the peptides
containing the unmodified and possibly substituted
methionines, these changes were present at < 2% of the
whole protein amount. A mass increase of 57 Da was
detected at the peptide LFDNAMLR. It could be localized
at the N terminus of the peptide and it is supposed to be
an artefact of the alkylation step during sample prepara-
tion. All modifications were partial; in each case peptides
with both modified and unmodified residues were
present. LC-MS/MS spectra for all modified peptides are
available as supplementary material.
MALDI analysis of Genotropin®
Approximately 96 spots were excised from a 2D gel with a
sample load of 1 mg Gentotropin®  and identified by
MALDI-TOF on the basis of peptide mass matching [24]
following in gel digestion with trypsin. Those samples
which were analysed by peptide mass fingerprinting from
MALDI-TOF were additionally analysed using LIFT-TOF/
TOF MS/MS from the same target. A maximum of three
precursor ions per sample were chosen for MS/MS
analysis.
Genotropin® was unambiguously identified by MS and
MS/MS Data (Figure 4 and 5), with a maximum of 24
matching peptides, representing a sequence- coverage of
86% to human growth hormone sequence present in
database (Figure 4, Table 3). All picked and analysed spots
showed similar peptide mass fingerprints. Only the oxida-
tion status of M varied, represented by a mass difference
(∆M) of 16 Da. Oxidation at M14 was demonstrated in
59,52% of analysed spots, 80,91% of M125 and 54,87% of
M170 showed oxidation too (Table 3). Neither changes in
amino acid sequence, nor post translational modifica-
tions like phosphorylation or deamidation could be
detected by this method.
Discussion
The dominant protein in the Genotropin® preparation has
an average molecular mass of 22127 Da. Electrospray LC-
MS/MS evaluation of the trypsinized recombinant human
growth hormone (rhGH) resulted in the identification of
amino acid substitutions at residues M14, M125 and M170.
Di-methylation of K70 or exchange to arginine, deamida-
tion of N149 and N152, and oxidation of M14, M125 and
M170  were also observed. These sequence alteration
account for 2% of the recombinant protein.
Amino acid exchanges of a rhGH has been described
before: Gellerfors et al. (1990) describe exchanges rhGH
Q65_V65 and rhGH Q66_K66[25]. Since the product was
not identified we cannot compare our results. Binding of
Table 2: Results of electrospray LC-MS/MS and MALDI-TOF MS/MS measurements
Sequence M calculated (Da) M observed (Da) delta M (Da) Modification
EETQQKSNLELLR 1586.83 1614.74 27.91 K70: di-methylation or → R *
FDTNSHNDDALLK 1488.68 1489.60 0.92 N149 / N152 deamidation
RLEDGSPR 928.47 900.46 -28.01 R127→ Q or K *
LFDNAMLR 978.50 994.40 15.90 M14 : oxidation
DMDKVETFLR 1252.61 1268.40 15.79 M170: oxidation
DLEEGIQTLMGR 1360.61 1376.66 16.05 M125: oxidation
LFDNAMLR 978.50 960.40 -18.10 M14 → I
DLEEGIQTLMGR 1360.61 1342.60 -18.01 M125 → I
DMDKVETFLR 1252.61 1234.60 -18.01 M170 → I
LFDNAMLR 978.50 1035.40 56.90 Carbamidomethyl – N terminus
• Nearly isobaric mass differences
Sequences and mass differences of modified peptides detected in the Genotropin sample. Column 1: sequence of modified peptides following 
tryptic digestion of Genotropin®; column 2: calculated monoisotopic masses of the unmodified tryptic peptides; column 3: observed monoisotopic 
masses; column 4: differences of calculated and observed masses; column 5: possible explanations of the mass differences.Proteome Science 2005, 3:1 http://www.proteomesci.com/content/3/1/1
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recombinant human growth hormone to the GH receptor
may be modified by the five amino acid exchanges
observed in the present study. Pal et al. (2003) calculated
binding energy differences between modified human
growth hormone (hGHv; M14_W14) and wild type human
growth hormone (hGHwt; M14) with the result that the
hGHv had more binding affinity to its receptor than
hGHwt [26,27]. Cunningham et al. showed that M14
influenced binding, even if it is not a "hot spot" for
linkage to its receptor. Furthermore, the amino acid
exchanges detected may very well lead to antigenic differ-
ences and thus form the molecular basis for eliciting
immune responses.
The underlying cause of amino acid exchanges may be
codon usage and/or absence of copy editing in E. coli: The
M_I exchanges may be due to miscast of the third nucleo-
side of the cognate anticodon at the so-called Wobble-
position, i.e. switch cytosine to guanine/adenosine, a phe-
nomenon described by Crick as "Wobble- hypothesis
[28]. Crick (1966) postulated a certain amount of wobble
at the third base position of the codon allowing more
than one possible codon-anticodon- base pairing.
Methionine (M)_I exchange of rhGH Genotropin® may
have been generated as the base pair G-G / G-A was replac-
ing G-C. Arginine (R)_K/Q and R_G exchanges of rhGH
Genotropin® may be due to difficulties in translation of
the rare codon AGG. Kane et al. (1995) predicted transla-
Electrospray LC-MS/MS spectrum of the modified peptide EETQQK*SNLELLR Figure 2
Electrospray LC-MS/MS spectrum of the modified peptide EETQQK*SNLELLR. Positive ionization product ion 
spectrum of the tryptic peptide m/z 808.4 generated by a linear ion trap mass spectrometer. Intensive y fragment ions verify 
that the K170 residue shows a mass increment of 28 Da compared to its theoretical mass.
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tional problems with an abundant mRNA species contain-
ing an excess of rare tRNA codons that may arise after the
initiation of transcription of a cloned heterologous gene
in the E. coli host [21]. Recent studies suggest clusters of
AGG/AGA codons can reduce both quantity and quality
of the synthesized protein [22,29]. Translational modifi-
cation normally does not include amino acid exchanges
but rather frameshift mutations/deletions [21,29-31].
In summary, we found two different pathways for amino
acid exchanges in Genotropin®: translation errors due to
usage of (1) the rare codon AGG in E. coli and (2) incor-
rect codon usage consisted with Crick's "Wobble-hypoth-
esis".
Oxidative modification of a recombinant human growth
hormone has been described by Karlsson et al. (1999)
who demonstrated M14 and M125 oxidation as detected by
LC-MS [32]. No other group have reported oxidation of
M170 as in our study. Indeed Teh et al. (1987) oxidised
natural hGH extracted from pituitary glands and detected
M14 and M125 oxidation by reversed phase chromatogra-
phy [33]. Gellerfors et al. (1990) oxidised rhGH with
hydrogen peroxide but again failed to show oxidation of
M170, as detected by reversed phase chromatography [25].
It is not known whether oxidation of methionines in
recombinant human growth hormone leads to functional
impairment but conformational changes are unlikely as
Electrospray LC-MS/MS spectrum of the peptide LFDNAM*LR Figure 3
Electrospray LC-MS/MS spectrum of the peptide LFDNAM*LR. Positive ionization product ion spectrum of the tryp-
tic peptide m/z 482.3 generated by a linear ion trap mass spectrometer. Ions of the y series verify the mass discrepancy of -18 
Da at the M14 residue compared to its theoretical value.
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proposed by circular dichroism and 1H-NMR studies [33].
It is worth mentioning that oxidised methionines are not
localised at the receptor binding site.
Post translational modification such as N-acetylation, N-
glycosylation, deamidation and oxidation have been
reported for rhGH, hGH and bovine growth hormone
(bGH) [15-17,34]. Dimethylation of K70 in rhGH and
hGH have not previously been reported.
Whether transmethylation occurred during processing or
is a post translational event during rhGH production in E.
coli is unknown. Nevertheless, Martal et al. (1985)
demonstrated reduction of biological activity of hGH and
bGH by methylation and ethylation of its residues K41,
K70, and K115[35]. Therefore, dimethylation of K70 in Gen-
otropin® could have biological relevance, probably reduc-
ing its pharmacotherapeutic activity.
Deamidation of N149 and N152 may be due to technical
processing, probably by heat treatment or lyophilisation
MS spectrum of Genotropin showing oxidation of M14, M125 and M170 Figure 4
MS spectrum of Genotropin showing oxidation of M14, M125 and M170.(a) MS spectrum of Genotropin® generated by 
an Ultraflex™ TOF/TOF (Bruker Daltonics) operated in the reflector mode for MALDI-TOF peptide mass fingerprint (PMF). 
Enlarged sections (b-d) from PMF of Genotropin® showing oxidised/non-oxidised status (ÄM+16Da) of Methionine. (b) first 
peak: LFDNAMLR (979.529 Da)/ second peak: LFDNAMLR + oxidation of Methionine (995.519 Da); (c) first peak: DMDKVET-
FLR (1253.587 Da) / second peak: DMDKVETFLR + oxidation of Methionine (1269.572); (d) first peak: SVFANSLVYGASDSN-
VYDLLKDLEE-GIQTLMGR (3605.040) / second peak: SVFANSLVYGASDSNVYDLLKDLEE-GIQTLMGR + oxidation of 
Methionine (3621.064)
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MS/MS spectra of Genotropin® Figure 5
MS/MS spectra of Genotropin® .LIFT-TOF/TOF (MS/MS) (a, b) spectra of Genotropin® generated by an Ultraflex™ TOF/
TOF (Bruker Daltonics) operated in LIFT mode for MALDI-TOF/TOF fully automated using the FlexControl™ software. The 
parent ions (m/z 1205.56 and m/z 2342.12) were selected for further analysis by MS/MS and the amino acid sequences 
NYGLLYCFR (5a) and LHQLAFDTYQEFEEAYIPK (5b) were unambiguously assigned to human growth hormone.
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and has already been reported by Gellerfors et al (1990)
and Karlsson et al. (1999) [25,32]. Though these appear
to have no function significance [26,27,36].
Modifications of the recombinant human growth hor-
mone, as shown in this study, may effect functionality and
safety depending on the prevalence of such forms in the
preparation. As already mentioned above, impaired bind-
ing to the receptor, conformational changes leading to
impaired function, amino acid exchanges as mutations
may well lead to immune phenomena or even disease [1-
3,37]. In addition, such modifications may act as markers
of these proteins in situations like rhGH doping.
Conclusions
Using one- and two-dimensional gel electrophoresis, elec-
trospray LC-MS, LC- MS/MS and MALDI-TOF-TOF mass
spectrometry we detected a series of modifications of the
recombinant human growth hormone (Genotropin®)
including amino acid exchanges, oxidation, di-methyla-
tion and deamidation. This analytical battery is a reliable,
specific and sensitive analytical tool for this purpose.
Methods
Sample preparation
Genotropin © MiniQuick 1,0 mg (Pharmacia & Upjohn;
Stockholm, Sweden) was suspended in 0,5 ml of sample
buffer consisting of 8 M urea (Merck, Darmstadt, Ger-
many), 4% CHAPS (3- [(3-cholamidopropyl) dimethyl-
ammonio]-1-propane-sulfonate) (Sigma, St. Louis, MO,
USA), 10 mM 1,4-dithioerythritol (Merck, Germany) and
0,5% carrier ampholytes "Resolyte" 3,5–10 (BDH Labora-
tory Supplies, Electran ®, England). The suspension was
transferred into Ultrafree-4 centrifugal filter units (Milli-
pore, Bedford, MA), for desalting and concentrating pro-
teins. Protein content of the supernatant was quantified
by the Bradford protein assay system [38]. The standard
curve was generated using bovine serum albumin and
absorbance was measured at 595 nm.
One-dimensional SDS-polyacrylamide gel electrophoresis
One dimensional SDS-polyacrylamide gel was performed
as described by Laemmli [39]. Samples of 0.5, 1, 2, 5, 10,
30, 50 and 100 µg were loaded on the gel. For determina-
tion of molecular weight 10 µl of precision plus protein
Table 3: Sequence coverage and peptide masses of Genotropin® 
Sequence Coverage: 86%
Matched peptides shown in Bold
1 FPTIPLSRLF DNAMLRAHRL HQLAFDTYQE FEEAYIPKEQ KYSFLQNPQT
51 SLCFSESIPT PSNREETQQK SNLELLRISL LLIQSWLEPV QFLRSVFANS
101 LVYGASDSNV YDLLKDLEEG IQTLMGRLED GSPRTGQIFKQTYSKFDTNS
151 HNDDALLKNY GLLYCFRKDM DKVETFLRIV QCRSVEGSCG F
Start – End Observed Mr(expt) Mr(calc) Delta Miss Sequence
1–8 930.61 929.60 929.53 0.07 0 FPTIPLSR
1–16 1906.97 1905.96 1906.01 - 0.05 1 FPTIPLSRLFDNAMLR Oxidation (M)
9–16 979.51 978.50 978.50 0.01 0 LFDNAMLR
17–38 2706.34 2705.33 2705.32 0.00 1 AHRLHQLAFDTYQEFEEAYIPK
20–38 2342.12 2341.11 2341.13 - 0.02 0 LHQLAFDTYQEFEEAYIPK
20–41 2727.35 2726.34 2726.32 0.02 1 LHQLAFDTYQEFEEAYIPKEQK
39–64 3058.51 3057.50 3057.45 0.05 1 EQKYSFLQNPQTSLCFSESIPTPSNR
42–64 2673.26 2672.26 2672.25 0.00 0 YSFLQNPQTSLCFSESIPTPSNR
42–70 3416.79 3415.78 3415.60 0.18 1 YSFLQNPQTSLCFSESIPTPSNREETQQK
65–77 1587.80 1586.79 1586.83 - 0.03 1 EETQQKSNLELLR
78–94 2055.19 2054.18 2054.19 - 0.01 0 ISLLLIQSWLEPVQFLR
95–115 2262.09 2261.08 2261.12 - 0.04 0 SVFANSLVYGASDSNVYDLLK
95–127 3621.02 3620.02 3619.77 0.25 1 SVFANSLVYGASDSNVYDLLKDLEEGIQTLMGR Oxidation (M)
116–127 1377.62 1376.62 1376.66 - 0.05 0 DLEEGIQTLMGR Oxidation (M)
141–158 2097.01 2096.00 2095.98 0.02 1 QTYSKFDTNSHNDDALLK
146–158 1489.66 1488.65 1488.68 - 0.03 0 FDTNSHNDDALLK
146–167 2676.26 2675.25 2675.24 0.01 1 FDTNSHNDDALLKNYGLLYCFR
159–167 1205.56 1204.55 1204.57 - 0.02 0 NYGLLYCFR
159–168 1333.64 1332.63 1332.66 - 0.03 1 NYGLLYCFRK
169–178 1253.58 1252.57 1252.61 - 0.04 1 DMDKVETFLR
169–178 1269.57 1268.56 1268.61 - 0.04 1 DMDKVETFLR Oxidation (M)
Sequence coverage of 86% and 21 matching peptides of Genotropin® to human growth hormone could be detected using MALDI MS/ MS-MS data.Proteome Science 2005, 3:1 http://www.proteomesci.com/content/3/1/1
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standards, all blue (Bio Rad, California, USA), were
applied on the gels.
Two-dimensional gel electrophoresis (2-DE)
2 DE was performed essentially as reported [40]. Samples
of 1 mg protein were applied on immobilized pH 3–10
nonlinear gradient strips in sample cups at their basic and
acidic ends. Focusing was started at 200 V and the voltage
was gradually increased to 8000 V at 4 V/min and then
kept constant for a further 3 h (approximately 150,000 Vh
totally). After the first dimension, strips (18 cm) were
equilibrated for 15 min in the buffer containing 6 M urea,
20% glycerol, 2% SDS, 2% DTT and then for 15 min in the
same buffer containing 2.5% iodoacetamide instead of
DDT. After equilibration, strips were loaded on 9–16%
gradient sodium dodecylsulfate polyacrylamide gels for
second-dimensional separation. The gels (180 × 200 × 1.5
mm) were run at 40 mA per gel. Immediately after the sec-
ond dimension run, gels were fixed for 12 h in 50% meth-
anol, containing 10% acetic acid, the gels were stained
with Colloidal Coomassie Blue (Novex, San Diego, CA)
for 12 h on a rocking shaker. Molecular masses were deter-
mined by running standard protein markers (Biorad Lab-
oratories, Hercules, CA) covering the range 10–250 kDa.
pI values were used as given by the supplier of the immo-
bilized pH gradient strips (Amersham Bioscience, Upp-
sala, Sweden). Excess of dye was washed out from the gels
with distilled water and the gels were scanned with Imag-
eScanner (Amersham Bioscience).
Electronic images of the gels were recorded using Adobe
Photoshop and Microsoft Power Point Softwares.
Matrix-assisted laser desorption ionisation mass 
spectrometry
Spots were excised with a spot picker (PROTEINEER sp™,
Bruker Daltonics, Germany), placed into 96-well micro-
titer plates and in-gel digestion and sample preparation
for MALDI analysis were performed by an automated pro-
cedure (PROTEINEER dp™, Bruker Daltonics) [41,42].
Briefly, spots were excised and washed with 10 mM
ammonium bicarbonate and 50% acetonitrile in 10 mM
ammonium bicarbonate. After washing, gel plugs were
shrunk by addition of acetonitrile and dried by blowing
out the liquid through the pierced well bottom. The dried
gel pieces were reswollen with 40 ng/µl trypsin (Promega,
U.S.A.) in enzyme buffer (consisting of 5 mM Octyl β-D-
glucopyranoside (OGP) and 10 mM ammonium bicarbo-
nate) and incubated for 4 hrs at 30°C. Peptide extraction
was performed with 10 µl of 1% TFA in 5 mM OGP.
Extracted peptides were directly applied onto a target
(AnchorChip™, Bruker Daltonics) that was load with α-
cyano-4-hydroxy-cinnamic acid (Bruker Daltonics) matrix
thinlayer. The mass spectrometer used in this work was an
Ultraflex™ TOF/TOF (Bruker Daltonics) operated in the
reflector mode for MALDI-TOF peptide mass fingerprint
(PMF) or LIFT mode for MALDI-TOF/TOF fully auto-
mated using the FlexControl™ software. An accelerating
voltage of 25 kV was used for PMF. Calibration of the
instrument was performed externally with [M+H]+ ions of
angiotensin I, angiotensin II, substance P, bombesin, and
adrenocorticotropic hormones (clip 1–17 and clip 18–
39). Each spectrum was produced by accumulating data
from 200 consecutive laser shots. Those samples which
were analysed by PMF from MALDI-TOF were addition-
ally analysed using LIFT-TOF/TOF MS/MS from the same
target. A maximum of three precursor ions per sample
were chosen for MS/MS analysis. In the TOF1 stage, all
ions were accelerated to 8 kV under conditions promoting
metastable fragmentation. After selection of jointly
migrating parent and fragment ions in a timed ion gate,
ions were lifted by 19 kV to high potential energy in the
LIFT cell. After further acceleration of the fragment ions in
the second ion source, their masses could be simultane-
ously analysed in the reflector with high sensitivity. PMF
and LIFT spectra were interpreted with the Mascot soft-
ware (Matrix Science Ltd, London, UK). Database
searches, through Mascot, using combined PMF and MS/
MS datasets were performed via BioTools 2.2 software
(Bruker). A mass tolerance of 100 ppm and 2 missing
cleavage sites for PMF and MS/MS tolerance of 0.5 Da and
1 missing cleavage sites for MS/MS search were allowed
and oxidation of methionine residues was considered.
The probability score calculated by the software was used
as criterion for correct identification.
The algorithm used for determining the probability of a
false positive match with a given mass spectrum is
described elsewhere [43].
Nano-electrospray LC-MS and LC-MS/MS analysis
Genotropin® MiniQuick 0.6 mg (Pharmacia & Upjohn;
Stockholm, Sweden) was suspended in the solution pro-
vided in the two-chamber cartridge and diluted with 1%
formic acid (Merck; Darmstadt, Germany) in water
(Maxima, Elga; High Wycombe, UK) to 1 pM/µl. 1 µl of
this solution was used for the nano-electrospray LC-MS
investigation. The HPLC used was an UltiMate™ system
(Dionex Corporation; Sunnyvale, CA, USA) equipped
with a PepMap C18 purification column (300 µm × 5
mm) and a 75 µm × 150 mm analytical column of the
same material. 0.1% TFA (Pierce Biotechnology Inc.;
Rockford, IL, USA) was used on the Switchos module for
the binding of the peptides and a linear gradient of ace-
tonitrile (Chromasolv®, Sigma-Aldrich; Seelze, Germany)
and 0.1% formic acid in water was used for the elution.
The gradient was (A = 5% acetonitrile / 0.1% formic acid
in water; B = 80% acetonitrile / 0.1% formic acid in water)
0% B for 12 min, 80% B in 30 min, 100 % B in 3 min,
100% B for 10 min, 0% B in 2 min, 0% B for 23 min. TheProteome Science 2005, 3:1 http://www.proteomesci.com/content/3/1/1
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flow rate was 240 nl/min. The LC-system was coupled on-
line to a QSTAR Pulsar hybrid mass spectrometer (Applied
Biosystems; Foster City, CA, USA). The nanospray source
of Proxeon (Odense, Denmark) was used with the distal
coated silica nanospray capillaries of New Objective
(Woburn, MA, USA). The electrospray voltage was set to
1800 V. Spectra were acquired over the mass range of m/z
600–1600. The accumulation time was 1 sec. Protein
spectra were deconvoluted by Analyst® (Applied Biosys-
tems; Foster City, CA, USA). LC-MS/MS analyses were car-
ried out also with the UltiMate™ system interfaced to the
QSTAR Pulsar or to an LTQ (Thermo; San Jose, CA, USA)
linear ion trap mass spectrometer. The gradient was (A =
5% acetonitrile / 0.1% formic acid in water B = 80% ace-
tonitrile / 0.1% formic acid in water) 0% B for 12 min,
60% B in 88 min, 100 % B in 5 min, 100% B for 10 min,
0% B in 5 min, 0% B for 20 min. Peptide spectra were
recorded over the mass range of m/z 450–1300, MS/MS
spectra were recorded in information dependent data
acquisition over the mass range of m/z 50–1600. One
peptide spectrum was recorded followed by two MS/MS
spectra on the QSTAR Pulsar instrument; the accumula-
tion time was 1 sec for peptide spectra and 2 sec for MS/
MS spectra. The collision energy was set automatically
according to the mass and charge state of the peptides
chosen for fragmentation. One full spectrum was
recorded followed by 3 MS/MS spectra on the LTQ instru-
ment, automatic gain control was applied and the colli-
sion energy was set to the arbitrary value of 35. Doubly or
triply charged ions were selected for product ion spectra.
MS/MS spectra were interpreted by Mascot (Matrix Sci-
ence Ltd, London, UK).
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